TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Gland Pharma Ltd.

GLAND on NSE · 19 Nov 2026

NIFTY 500

3,292.90 ▲ +1.93 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

31 filings of GLAND since February 2025.

board outcome 13, presentation 8, transcript 8, results 2

FiledTypeSubject
12 Nov 2026transcript
Capex, Guidance, Management change, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q2 FY27 earnings call held on November 06, 2026.

Management reported Q2 FY27 revenue of INR 18,336 million (up 23% YoY), reported EBITDA of INR 4,804 million, adjusted EBITDA of INR 5,030 million (27% margin) and profit after tax of INR 2,908 million (up 58% YoY).

Management said CDMO revenue grew 31% YoY to INR 8,227 million, and US revenue grew 42% YoY to INR 11,795 million.

Management said Cenexi posted quarterly revenue of EUR 41 million and an EBITDA loss of EUR 6 million due to planned shutdowns, and expects profitability to be restored from Q3.

Management said a brownfield capex of approximately INR 10,000 million is being initiated at Pashamylaram, with commercial operations from FY2030, and that Board approval for additional Vizag capex will be sought in the coming quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2026presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its investor presentation on Q2 FY27 financial results, dated 6 November 2026, under Regulation 30 of the SEBI LODR Regulations.

Q2 FY27 consolidated revenue from operations was ₹18,336 Mn, up 23% YoY from ₹14,869 Mn; PAT was ₹2,908 Mn, up 58% YoY, with PAT margin of 16%.

Q2 FY27 EBITDA was ₹4,804 Mn (26% margin), up 53% YoY; Adj. EBITDA was ₹5,030 Mn (27% margin), up 50% YoY.

6M FY27 revenue from operations was ₹36,339 Mn, up 21% YoY; 6M FY27 PAT was ₹6,077 Mn, up 52% YoY.

Q2 FY27 CDMO revenue was ₹8,227 Mn (up 31% YoY) and Critical Injectables revenue was ₹10,109 Mn (up 18% YoY); management attributed CDMO growth to recent product launches and higher volumes, and Critical Injectables growth to new launches and higher demand from existing customers.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2026board outcome
Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Gland Pharma's board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 on November 06, 2026, with the Deloitte Haskins & Sells limited review report, and the press release and investor presentation were filed.

Consolidated revenue from operations for the quarter ended September 30, 2026 was Rs 18,335.88 million, against Rs 18,002.71 million for the quarter ended June 30, 2026 and Rs 14,868.75 million for the quarter ended September 30, 2025.

Consolidated profit for the period for the quarter ended September 30, 2026 was Rs 2,907.56 million, against Rs 3,169.59 million for the quarter ended June 30, 2026 and Rs 1,836.84 million for the quarter ended September 30, 2025.

Consolidated revenue from operations for the half year ended September 30, 2026 was Rs 36,338.59 million, against Rs 29,924.97 million for the half year ended September 30, 2025.

The board meeting commenced at 15.00 hrs IST and ended at 16.15 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Oct 2026board outcome
Acquisition, Management change
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.
AI summary

Gland Pharma Limited's board approved on October 01, 2026 an investment of USD 21 million by the company in Gland Pharma USA Inc. (Gland USA), to be used to subscribe to 60% of the equity of Novelstar Pharma Inc., a newly incorporated US company, to facilitate expansion in the United States.

Gland USA's share capital rises from USD 500,000 to USD 21,500,000 after the investment; its FY2025-26 turnover is nil. The investment is cash-funded and expected to complete by October 31, 2026.

The board also accepted the resignation of non-executive, non-independent director Mr. Wenjie Zhang with immediate effect, citing pre-occupations.

Mr. Xingli Wang (DIN: 11899926) was appointed as an additional non-executive, non-independent director effective October 01, 2026, subject to member approval by postal ballot.

Board committees were realigned with effect from October 01, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Sep 2026board outcome
Acquisition
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026.
AI summary

Gland Pharma Limited's board, at a meeting held on September 13, 2026, approved acquiring 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd, both wholly-owned subsidiaries, so that Gland US becomes a direct wholly-owned subsidiary.

Cost of acquisition is USD 5,01,208 in cash; the target's share capital is USD 5,00,000 and its FY26 turnover is nil.

The company expects to complete the acquisition by October 31, 2026; no governmental or regulatory approvals are required.

The company says the transaction is a related party transaction at arm's length, priced by an independent valuer, and is intended to remove layers and streamline the corporate structure with no material impact on business.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Aug 2026transcript
Acquisition, Capex, Guidance, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q1FY27 earnings conference call held on August 10, 2026, covering the quarter ended June 30, 2026.

Management (Executive Chairman Srinivas Sadu) reported revenue of INR18,003 million, up 20% year-on-year, adjusted EBITDA of INR5,102 million (28% margin) and profit after tax of INR3,170 million, up 47% year-on-year (18% PAT margin).

Management said CDMO revenue was INR8,915 million (up 20%) and B2B revenue was INR9,088 million (up 19%); U.S. revenue was INR9,810 million (up 32%) and Europe and other regulated markets INR4,488 million (up 11%).

Management said revenues in rest of world markets were INR3,039 million, impacted by supply disruptions in Saudi Arabia, and that a strategic manufacturing and supply agreement with a global pharmaceutical company is expected to generate revenue from calendar year 2029, with revenue potential of approximately USD90 million to USD100 million once all products are commercialized.

Management said it is progressing multiple brownfield and greenfield capacity expansion initiatives.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its investor presentation on Q1 FY27 financial results, dated August 10, 2026, under Regulation 30 of the SEBI LODR Regulations.

Consolidated revenue from operations for Q1 FY27 was ₹18,003 million, up 20% YoY from ₹15,056 million and up 3% QoQ from ₹17,428 million.

Consolidated PAT for Q1 FY27 was ₹3,170 million, up 47% YoY from ₹2,155 million, and down 14% QoQ from ₹3,667 million; PAT margin was 18%.

Adjusted EBITDA for Q1 FY27 was ₹5,102 million (28% margin), up 37% YoY and down 3% QoQ; gross profit margin was 65%.

Net worth was ₹106,762 million at Jun'26, and net cash was ₹32,939 million, with capital expenditure of ₹1,132 million in Q1 FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026board outcome
Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Gland Pharma Limited filed the outcome of its board meeting held on August 10, 2026, which approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with Limited Review Reports from Deloitte Haskins & Sells.

The consolidated statement shows total income of Rs 18,002.71 million for the quarter ended June 30, 2026 (the first column, with the figures as extracted from the OCR text), with profit for the quarter of Rs 2,902.42 million attributable to owners of the company (extracted figures may be garbled).

The auditor's review notes that two subsidiaries had total revenues of Rs 1,654.54 million, total profit after tax of Rs 82.44 million and total comprehensive income of Rs 82.44 million for the quarter, reviewed by another auditor.

A press release and investor presentation on the results were also filed; management commentary from these was not included in the pages provided.

The board meeting commenced at 15.00 hrs IST and ended at 16.05 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Jun 2026board outcome
Management change
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 15, 2026.
AI summary

Board of Gland Pharma Limited approved re-appointment of Mr. Udo Jahannes Vetter as Independent Director for a second five-year term from July 21, 2026 to July 20, 2031, subject to member approval by postal ballot.

Board appointed Mr. William Robert Keller as Additional Director (Non-Executive - Independent) with effect from June 15, 2026, subject to member approval by postal ballot.

Independent Director Mr. C.S.N. Murthy resigned effective close of business hours on June 15, 2026, citing a possible future conflict of interest because a company of which Mr. Satyanarayana Murthy Chavali is Promoter and Director plans to enter a business segment that may overlap with Gland's contemplated business; he confirmed no other material reasons.

Mr. Essaji Goolam Vahanvati was appointed to the board of Gland Pharma International Pte. Ltd, a material subsidiary, with effect from June 15, 2026, and Board committees were realigned with effect from June 15, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2026transcript
Capex, Guidance, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q4 FY26 earnings conference call, held on May 15, 2026.

Management reported Q4 FY26 revenue of INR17,428 million (up 22% year-on-year), adjusted EBITDA of INR5,244 million (30% margin) and adjusted PAT of INR3,667 million (21% margin).

For full year FY26, management reported revenue of INR64,307 million (up 14.5%), adjusted EBITDA of INR16,826 million (26% margin) and adjusted PAT of INR10,455 million (16% margin).

Management said the CDMO business was 46% of total revenue in FY26, growing 28%, and that it plans capex of INR2,000 crores over the next five years for capacity expansion.

Management said Cenexi revenue was EUR45 million in Q4 (up 4%) with EBITDA of EUR1 million, in line with guidance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2026presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its investor presentation on Q4 FY26 and FY26 financial results, dated 15 May 2026, under Regulation 30 of the SEBI LODR Regulations.

Consolidated revenue from operations was ₹17,428 Mn in Q4 FY26, up 22% YoY, and ₹64,307 Mn in FY26, up 14% YoY.

Consolidated Adj. EBITDA was ₹5,244 Mn in Q4 FY26 (30% margin) and ₹16,826 Mn in FY26 (26% margin).

Consolidated Adj. PAT was ₹3,667 Mn in Q4 FY26, up 97% YoY, and ₹10,455 Mn in FY26, up 50% YoY.

Base business (Gland) revenue from operations was ₹12,648 Mn in Q4 FY26, up 22% YoY, and ₹45,613 Mn in FY26, up 11% YoY.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2026board outcome
Dividend / buy-back, Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Gland Pharma's board on May 15, 2026 approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified audit opinions; the press release and investor presentation were enclosed, but their figures are not in the pages provided.

The board recommended a final dividend of Rs. 20 per equity share of Rs. 1 each (2000%) for FY2025-26, payable within 30 days of the 48th AGM if approved by shareholders.

The record date for the final dividend is Tuesday, August 11, 2026.

The 48th AGM will be held via video conferencing/OAVM on Tuesday, August 25, 2026.

The board meeting commenced at 15:00 IST and ended at 16:10 IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Apr 2026board outcome
Management change
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 09, 2026.
AI summary

Gland Pharma Limited's board, at its meeting on April 09, 2026, approved the re-appointment of Ms. Naina Lal Kidwai (DIN: 00017806) as an Independent Director for a second term of five consecutive years.

The re-appointment is effective from May 17, 2026 till May 16, 2031.

Approval of the members under Regulation 25(2A) of the Listing Regulations will be obtained through a postal ballot and e-voting.

Annexure-A gives her brief profile, including that she is a Non-Executive Director on the Boards of Holcim, Gland Pharma, UPL and Biocon.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026transcript
Capex, Guidance, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q3 FY26 earnings conference call, held January 28, 2026.

Management said Q3 FY26 revenue grew 22% year-on-year to INR 16,954 million and adjusted EBITDA rose 25% to INR 4,490 million, with adjusted EBITDA margin of 26%.

For the 9 months ended FY26, consolidated revenue was INR 46,879 million (up 12%) and adjusted EBITDA was INR 11,582 million (up 26%).

Management plans to invest approximately INR 2,000 crore in capex over the next 5 years, mainly in BFS and ophthalmic lines and CDMO contracts.

Management said Cenexi delivered Q3 revenue of EUR 50 million and EBITDA of EUR 1 million, in line with guidance, and expects Cenexi to remain on a growth trajectory.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jan 2026presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its investor presentation on Q3 and 9M FY26 financial results, dated 28 January 2026.

Consolidated Q3 FY26 revenue from operations was ₹16,954 Mn, up 22% YoY, with Adj. EBITDA of ₹4,490 Mn (26% margin) and Adj. PAT of ₹2,797 Mn (16% margin), up 37% YoY.

Consolidated 9M FY26 revenue from operations was ₹46,879 Mn, up 12% YoY, with Adj. PAT of ₹6,789 Mn, up 33% YoY.

Base business (Gland) Q3 FY26 revenue from operations was ₹11,790 Mn, up 16% YoY, with Adj. PAT of ₹3,274 Mn (28% margin).

The presentation contains no management commentary on outlook or guidance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jan 2026board outcome
Management change, Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Gland Pharma Limited filed the outcome of its board meeting held on January 28, 2026.

The board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review reports, plus a press release and investor presentation on the results.

The board reappointed Grant Thornton Bharat LLP as internal auditors for FY 2026-27, effective April 1, 2026.

The pages provided do not state the revenue, profit or other financial figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Nov 2025transcript
Acquisition, Capex, Guidance, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q2 FY26 earnings conference call, held on November 3, 2025.

Management said Q2 FY26 consolidated revenue was INR 14,869 million (up 6% YoY) and consolidated EBITDA was INR 3,139 million (21% margin); H1 FY26 revenue was INR 29,925 million (up 7%) with EBITDA of INR 6,817 million (23% margin).

Management said U.S. revenue rose 8% YoY to INR 8,005 million in Q2 and Cenexi revenue was EUR 88 million for H1 FY26 (up 10% YoY), with EBITDA losses reduced to EUR 5 million from EUR 11 million.

Management said it expects a stronger second half of FY26 and is evaluating inorganic growth opportunities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its investor presentation on Q2FY26 financial results dated 03 November 2025 under Regulation 30 of the SEBI LODR Regulations.

Consolidated revenue from operations for Q2 FY26 was ₹14,869 Mn, up 6% YoY from ₹14,058 Mn, and down 1% QoQ from ₹15,056 Mn.

Consolidated EBITDA for Q2 FY26 was ₹3,139 Mn (21% margin) versus ₹2,961 Mn a year earlier; Adj. EBITDA was ₹3,355 Mn (23% margin).

Consolidated PAT for Q2 FY26 was ₹1,837 Mn, up 12% YoY from ₹1,635 Mn, with a 12% PAT margin.

Base business (Gland) revenue from operations for Q2 FY26 was ₹10,767 Mn (up 1% YoY) and PAT was ₹3,055 Mn (up 7% YoY).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025board outcome
Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Gland Pharma's board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with Limited Review Reports from Deloitte Haskins & Sells.

The filing encloses a press release and investor presentation on the results; the board meeting ran from 15.00 to 16.10 Hrs IST on November 3, 2025.

Consolidated revenue from operations for the quarter ended September 30, 2025 is shown as ₹14,868.75 million (quarter ended June 30, 2025 ₹15,056.22 million is not separately labelled in the extracted text; the half-year figure is ₹29,924.97 million).

Consolidated profit for the period in the extracted table for the quarter ended September 30, 2025 is ₹1,836.84 million, with total comprehensive income of ₹2,865.11 million; the auditor's review notes losses at five subsidiaries.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Aug 2025transcript
Capex, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q1 FY26 earnings conference call held on August 5, 2025.

Management said consolidated revenue was INR 15,056 million, up 7% year-on-year, and consolidated EBITDA was INR 3,678 million, up 39%, with EBITDA margin rising from 19% to 24%.

Management said Cenexi returned to breakeven EBITDA in Q1 FY26, and the base business's U.S. revenue was INR 7,443 million (49% of business).

Management said other regulated markets grew 34% year-on-year and Rest of the World revenue was INR 2,978 million (up 5%), with softer order intake in some regions.

Management said the Company launched nine new products in the U.S. in Q1 FY26 and is expanding pen and cartridge capacity from 40 million to over 140 million units.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Aug 2025presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its Investor Presentation on Q1FY26 financial results, dated 05 August 2025, under Regulation 30 of the SEBI LODR Regulations.

Consolidated revenue from operations for Q1 FY26 was ₹15,056 Mn, up 7% YoY from ₹14,017 Mn, and EBITDA was ₹3,678 Mn (24% margin) versus ₹2,654 Mn (19%) a year earlier.

Consolidated PAT for Q1 FY26 was ₹2,155 Mn (14% PAT margin), up 50% YoY from ₹1,438 Mn.

Base business (Gland) revenue from operations was ₹10,409 Mn for Q1 FY26, up 3% YoY, with PAT of ₹2,692 Mn, up 20% YoY.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Aug 2025board outcome
Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Gland Pharma Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, on August 05, 2025, along with the Limited Review Reports, and a press release and investor presentation on the results were filed.

The consolidated statement shows revenue from operations of ₹15,056.22 million for the quarter ended June 30, 2025, against ₹14,017.10 million for the quarter ended June 30, 2024.

Consolidated profit for the quarter ended June 30, 2025 is shown as ₹1,315.66 million against ₹1,315.67 million in the preceding year's quarter column as printed; the figures are partly garbled in the OCR text and should be checked against the original.

The auditor Deloitte Haskins & Sells reported that nothing came to its attention causing it to believe the consolidated statement contains a material misstatement, with no modification of its conclusion.

The board meeting commenced at 15.00 Hrs IST and ended at 15.40 Hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 May 2025transcript
Capex, Guidance, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q4 FY25 earnings conference call, held on May 20, 2025.

Management reported Q4 FY25 consolidated revenue of INR 14,249 million and consolidated EBITDA of INR 3,475 million (24% margin); base business (excluding Cenexi) revenue fell 12% year-over-year to INR 10,332 million.

For full FY25, consolidated revenue was INR 56,165 million and EBITDA INR 12,689 million (23% margin); base business revenue was INR 41,248 million with a 35% EBITDA margin.

Management said it launched 31 new products in the US in FY25, entered the GLP-1 segment with liraglutide, and is scaling cartridge capacity from 40 million to an additional 100 million units by CY 2026.

Management acknowledged below-expectation performance at Cenexi and a shift toward higher-value products there.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2025presentation
Results
Gland Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Gland Pharma filed its Investor Presentation on Q4 and FY25 financial results, dated 20 May 2025.

Q4 FY25 consolidated revenue from operations was ₹14,249 Mn, down 7% YoY from ₹15,375 Mn, and up 3% QoQ from ₹13,841 Mn.

Q4 FY25 consolidated PAT was ₹1,865 Mn (13% margin), down 3% YoY from ₹1,924 Mn.

FY25 consolidated revenue from operations was ₹56,165 Mn, down 1% from ₹56,647 Mn in FY24; FY25 PAT was ₹6,985 Mn, down 10% from ₹7,725 Mn.

Q4 FY25 Base Business (Gland) revenue was ₹10,332 Mn, down 12% YoY; FY25 Base Business PAT was ₹10,868 Mn, up 4% YoY.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2025board outcome
Dividend / buy-back, Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Gland Pharma's board, meeting on May 20, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified auditor opinions; press release and investor presentation were enclosed.

The board recommended a final dividend of Rs. 18 per equity share of Rs. 1 each (1800%) for FY2024-25, with record date Thursday, August 14, 2025.

The 47th Annual General Meeting is scheduled for Thursday, August 28, 2025, via video conferencing/OAVM.

The board approved appointment of M/s. RVR & Associates as Secretarial Auditors for five years from April 1, 2025, subject to shareholder approval.

The Policy for determining Material Subsidiaries, Related Party Transactions policy, Insider Trading code and Whistle Blower Policy were amended.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Feb 2025board outcome
Acquisition
Gland Pharma Limited has informed the Exchange regarding Board meeting held on February 26, 2025.
AI summary

Gland Pharma's board, on the recommendation of the ESOP Compensation Committee, approved the Gland Pharma Employee Stock Option Scheme, 2025 for eligible employees of the company and its subsidiaries, subject to shareholder approval.

The scheme covers 29,82,124 shares in total; up to 19,68,202 options (66%) may be granted at an exercise price up to a maximum 50% discount to market price or Rs. 750, whichever is higher, and up to 10,13,922 options (34%) at face value.

Options vest not earlier than 1 year and not later than 4 years from grant, with an exercise period of maximum 2 years from vesting.

Shareholder approval will be sought through a postal ballot with remote e-voting; the board meeting ran from 14:00 to 14:30 IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Feb 2025transcript
Acquisition, Capex, Guidance, Legal, Management change, Results
Gland Pharma Limited has informed the Exchange about Transcript
AI summary

Gland Pharma filed the transcript of its Q3 FY25 earnings conference call, held on February 3, 2025.

Management said consolidated Q3 FY25 revenue was INR13,841 million with consolidated EBITDA of INR3,600 million (26% margin, up 100 bps year-on-year).

Management said base business revenue (excluding Cenexi) was INR10,123 million, down 8% year-on-year, due to volume degrowth in some key products, and the base business EBITDA margin was 39% versus 34% a year earlier.

Management said Cenexi revenue was EUR41 million in Q3 FY25, below estimates, due to reduced manufacturing after a regulatory audit at Fontenay, and it expects a weaker January-March quarter but targets positive EBITDA for FY26.

Management also reported receipt of US FDA EIR for the Dundigal and Pashamylaram facilities and a biologics CDMO collaboration with Dr. Reddy's Laboratories.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025results
Results
Integrated Filing Financial for the quarter and nine months ended December 31, 2024
AI summary

Gland Pharma filed its integrated filing (financials) for the quarter and nine months ended December 31, 2024, with an auditor's limited review report dated February 3, 2025.

Q3 FY25 consolidated revenue from operations was ₹13,840.52 million, against ₹15,451.55 million in the year-ago quarter and ₹14,058.33 million in the previous quarter.

Q3 FY25 consolidated profit for the period was ₹2,046.92 million, against ₹1,918.56 million a year earlier and ₹1,635.32 million in the previous quarter.

Nine-month consolidated revenue from operations was ₹41,915.95 million and profit for the period was ₹5,119.85 million, against ₹5,800.40 million in the nine months ended December 31, 2023.

Q3 FY25 basic earnings per share was ₹12.42 (not annualised).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025presentation
Capex, Guidance, Legal, Results
Gland Pharma Limited has informed the Exchange regarding 'Investor presentation'.
AI summary

Gland Pharma filed its investor presentation on Q3 and 9M FY25 financial results.

Consolidated Q3 FY25 revenue from operations was ₹13,841 Mn (down 10% YoY), PAT was ₹2,047 Mn (up 7% YoY) and EBITDA was ₹3,600 Mn (26% margin); 9M FY25 revenue was ₹41,916 Mn (up 2% YoY) and PAT was ₹5,120 Mn (down 12% YoY).

Base business (Gland) Q3 FY25 revenue was ₹10,123 Mn (down 8% YoY) with PAT of ₹2,864 Mn; the company launched 13 new molecules and received USFDA EIRs for its Dundigal and Pashamylaram facilities.

Q3 FY25 capex incurred was ₹1,379 Mn; R&D expenses were ₹437 Mn.

Management said Cenexi's Fontenay production was hit by an unannounced ANSM inspection and Braine-l'Alleud output remains affected by a lyophilizer breakdown, expected to be restored in H1 FY26; Cenexi targets positive EBITDA next fiscal year on revenue above €200 million.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025board outcome
Management change, Results
Gland Pharma Limited has informed the Exchange regarding Board meeting held on February 03, 2025.
AI summary

Gland Pharma's board on February 3, 2025 approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports, a press release and an investor presentation.

The board appointed Grant Thornton Bharat LLP as internal auditors for financial year 2025-26, effective April 1, 2025, citing rotation of internal auditors.

The board meeting commenced at 15.00 hrs IST and ended at 17.00 hrs IST.

The pages provided do not state the revenue or profit figures for the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025results
Management change, Results
Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Gland Pharma's board met on February 3, 2025 and approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a limited review report from Deloitte Haskins & Sells.

The company enclosed a press release and investor presentation on the results, but their figures (revenue, profit) are not included in the pages provided.

The board appointed Grant Thornton Bharat LLP as internal auditors for FY 2025-26, effective April 1, 2025, citing rotation of internal auditors.

The board meeting ran from 15.00 to 17.00 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in